Dr Kami Maddocks shares highlights from ASH 2025, including how the phase 3 EPCORE FL‑1 trial, adding a bispecific antibody to R2 in second‑line or later follicular lymphoma, showed significantly ...
Data on epcoritamab with rituximab and lenalidomide, results on a novel oral CELMoD agent, and outcomes from late-line CAR T-cell therapy are among highlights in follicular lymphoma (FL) presented at ...
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 2:45 P.M. EST) – Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive ...
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 4:30 P.M. EST) – A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply ...
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma. At ASH ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE ® FL-1 study evaluating fixed duration EPKINLY ® (epcoritamab-bysp) in ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Ann S. LaCasce, MD, MMSc, discusses highlights in mantle cell lymphoma presented at ASH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results